BioSpace News Archive

Pharm Country

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix, Inc. announced today a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections.

January 2, 2024
·
11 min read
Deals

Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.’s (OTCQB: ODYY) (“Odyssey”) proprietary neurological drug therapies and technologies.

January 2, 2024
·
8 min read
Drug Development

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Spero Therapeutics, Inc. announced the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections, including acute pyelonephritis.

January 2, 2024
·
7 min read
Genetown

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Akari Therapeutics, Plc announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.

January 2, 2024
·
5 min read
Drug Development

Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery PlatformBioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study

Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca.

January 2, 2024
·
5 min read
BioMidwest

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024

Alimera Sciences, Inc. announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.

January 2, 2024
·
5 min read
Biotech Bay

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 a.m. Pacific Time.

January 2, 2024
·
1 min read
Drug Development

atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced positive results from its Phase 1 study evaluating orally administered EMP-01, the R-enantiomer of MDMA (3,4-methylenedioxy-methamphetamine).

January 2, 2024
·
6 min read
Job Trends

AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024.

January 2, 2024
·
1 min read
Bio NC

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Verona Pharma plc, announces it and its wholly-owned subsidiary, Verona Pharma, Inc., have entered into a debt financing facility providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC and Hercules Capital, Inc.

January 2, 2024
·
9 min read